<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Perm Medical Journal</journal-id><journal-title-group><journal-title xml:lang="en">Perm Medical Journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Пермский медицинский журнал (сетевое издание "Perm medical journal")</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0136-1449</issn><issn publication-format="electronic">2687-1408</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">109360</article-id><article-id pub-id-type="doi">10.17816/pmj39341-54</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Literature review</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Обзор литературы</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">New-onset type ii diabetes mellitus in early diagnosis of pancreatic cancer: literature review</article-title><trans-title-group xml:lang="ru"><trans-title>Впервые выявленный сахарный диабет 2-го типа в раннем выявлении рака поджелудочной железы: обзор литературы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ponomarev</surname><given-names>P. A.</given-names></name><name xml:lang="ru"><surname>Пономарев</surname><given-names>П. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>surgeon, oncologist, postgraduate student, Department of Radiology, Surgery and Oncology</p></bio><bio xml:lang="ru"><p>хирург, онколог, аспирант кафедры радиологии, хирургии и онкологии</p></bio><email>surgepon@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Moiseenko</surname><given-names>V. E.</given-names></name><name xml:lang="ru"><surname>Моисеенко</surname><given-names>В. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Candidate of Medical Sciences, surgeon, oncologist of Surgery Unit № 2, Associate Professor of Department of Radiology, Surgery and Oncology</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук, хирург, онколог отделения хирургии № 2, доцент кафедры радиологии, хирургии и онкологии</p></bio><email>surgepon@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pavlovsky</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Павловский</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor of Department of Radiology, Surgery and Oncology, Chief Scientist of Surgery Unit № 2</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, профессор кафедры радиологии, хирургии и онкологии, научный руководитель отделения хирургии № 2</p></bio><email>surgepon@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Popov</surname><given-names>S. A.</given-names></name><name xml:lang="ru"><surname>Попов</surname><given-names>С. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Candidate of Medical Sciences, surgeon, oncologist of Surgery Unit № 2</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук, хирург, онколог отделения хирургии № 2</p></bio><email>surgepon@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Turlak</surname><given-names>A. S.</given-names></name><name xml:lang="ru"><surname>Турлак</surname><given-names>А. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>clinical resident, Department of Radiology, Surgery and Oncology</p></bio><bio xml:lang="ru"><p>клинический ординатор кафедры радиологии, хирургии и онкологии</p></bio><email>surgepon@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Granov</surname><given-names>D. A.</given-names></name><name xml:lang="ru"><surname>Гранов</surname><given-names>Д. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor, Academician of RAS, Chief Scientist</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, профессор, академик РАН, научный руководитель</p></bio><email>surgepon@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Russian Scientific Center of Radiology and Surgical Technologies named after Academician A.M. Granov</institution></aff><aff><institution xml:lang="ru">Российский научный центр радиологии и хирургических технологий &#13;
имени академика A.M. Гранова</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">The First Pavlov State Medical University of St. Petersburg</institution></aff><aff><institution xml:lang="ru">Первый Санкт-Петербургский медицинский университет имени академика И.П. Павлова</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-07-15" publication-format="electronic"><day>15</day><month>07</month><year>2022</year></pub-date><volume>39</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>41</fpage><lpage>54</lpage><history><date date-type="received" iso-8601-date="2022-07-15"><day>15</day><month>07</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-07-15"><day>15</day><month>07</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Ponomarev P.A., Moiseenko V.E., Pavlovsky A.V., Popov S.A., Turlak A.S., Granov D.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Пономарев П.А., Моисеенко В.Е., Павловский А.В., Попов С.А., Турлак А.С., Гранов Д.А.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Ponomarev P.A., Moiseenko V.E., Pavlovsky A.V., Popov S.A., Turlak A.S., Granov D.A.</copyright-holder><copyright-holder xml:lang="ru">Пономарев П.А., Моисеенко В.Е., Павловский А.В., Попов С.А., Турлак А.С., Гранов Д.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">http://creativecommons.org/licenses/by-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://permmedjournal.ru/PMJ/article/view/109360">https://permmedjournal.ru/PMJ/article/view/109360</self-uri><abstract xml:lang="en"><p>The literature data on the connection between type 2 diabetes mellitus (DM) and pancreatic cancer (PC) were analyzed. Early detection of pancreatic cancer remains an unsolved problem of oncology because of absence of pathognomonic symptoms for this disease at the early stages, difficulties in visualizing changes in the pancreas as well as difficulties in differential diagnosis with benign tumors. Fifty nine articles in Russian and English were studied, and the data presented in literature regarding the connection between type 2 diabetes mellitus and early stages of pancreaticic cancer have been analyzed.Resectable pancreatic cancer makes up less than 15 % of the cases during initial medical examination. Currently, the existing methods of diagnostics do not allow solving the problem of early detection of pancreatic cancer – it dictates the need to search for a new marker that will improve the early diagnosis of this tumor. According to the results of many studies, there has been detected a connection between the new-onset type 2 diabetes mellitus and early stages of pancreatic cancer. Based on the data published by a number of authors, manifestation of the new-onset type 2 diabetes mellitus in patients over fifty (fasting blood glucose level ≥ 7 mmol/L, or a blood glucose sugar level ≥ 11,1 mmol/L after performing oral glucose tolerance test, or random blood glucose level ≥ 11,1 mmol/L with a typical hyperglycemia signs and symptoms) can serve as an early symptom of pancreatic cancer.</p> <p>Thus, the new-onset type 2 diabetes mellitus in persons aged 50 years or older can potentially be used to identify a group of patients requiring a directional examination for the purpose of early detection of pancreatic cancer. Further studies on this problem could allow us to formulate a special program of early diagnostics of pancreatic cancer.</p></abstract><trans-abstract xml:lang="ru"><p>Проведен анализ литературных данных о связи между сахарным диабетом (СД) 2-го типа и раком поджелудочной железы (РПЖ). Раннее выявление РПЖ остается нерешенной проблемой онкологии, что обусловлено отсутствием патогномоничных симптомов для данного заболевания на ранних стадиях, а также сложностями в визуализации изменений поджелудочной железы и дифференциальной диагностике с доброкачественными нозологиями. Изучено 59 статей на отечественном и зарубежных языках, проведен анализ представленных в литературе данных о связи СД 2-го типа и ранних стадий РПЖ.</p> <p>На момент обращения за медицинской помощью, доля пациентов, у которых заболевание представлено резектабельными формами, составляет менее 15 %. В настоящее время существующие методы диагностики не позволяют решить данную проблему – это диктует необходимость поиска новых подходов, которые позволят повысить частоту раннего выявления РПЖ. По результатам исследований отмечена связь впервые выявленного СД 2-го типа и ранних стадий РПЖ. По данным ряда авторов, манифестация СД 2-го типа у лиц в возрасте &gt; 50 лет, определяемая по уровню глюкозы плазмы крови натощак ≥ 7,0 ммоль/л или уровню глюкозы плазмы крови ≥11,1 ммоль/л через 2 ч после нагрузки 75 г глюкозы, или уровню глюкозы плазмы крови ≥ 11,1 ммоль/л в случайном анализе при наличии классических признаков гипергликемии, или уровню гликированного гемоглобина HbA1C ≥ 6,5 %, – может являться ранним проявлением РПЖ.</p> <p>Таким образом, впервые выявленный СД 2-го типа у пациентов в возрасте старше 50 лет потенциально может использоваться для выделения группы больных, требующей направленного обследования. Дальнейшее изучение этого вопроса позволит разработать специализированную программу для раннего выявления РПЖ.</p></trans-abstract><kwd-group xml:lang="en"><kwd>pancreatic cancer</kwd><kwd>early diagnostics</kwd><kwd>diabetes mellitus</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак поджелудочной железы</kwd><kwd>раннее выявление</kwd><kwd>сахарный диабет</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021; 3: 209–249.</mixed-citation></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Kaprin A.D., Starinskiy V.V., Shakhzodova A.O. Malignant neoplasms in Russia in 2020 (morbidity and mortality) Moscow: MNIOI im. P.A. Gertsena − filial FGBU «NMITs radiologii» Minzdrava Rossii 2021; 252 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Каприн А.Д., Старинский В.В, Шахзодова А.О. Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России 2021; 252.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Moiseenko V.E., Pavlovskiy A.V., Granov D.A., Kochorova L.V., Dodonova I.V., Khizha V.V., Yazenok A.V., Yakovenko T.V. Analysis of statistics of indicators of the population of St. Petersburg, detection of malignant neoplasms of the pancreas. Vestnik Rossiyskoy Voenno-meditsinskoy akademii 2021; 2: 155–164 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Моисеенко В.Е., Павловский А.В., Гранов Д.А., Кочорова Л.В., Додонова И. В., Хижа В. В., Язенок А. В., Яковенко Т. В. Анализ статистических показателей населения Санкт-Петербурга, страдающих злокачественными новообразованиями поджелудочной железы. Вестник Российской Военно-медицинской академии 2021; 2: 155–164.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Tsimmerman Ya.S. Pancreatic cancer: terra incognita in modern gastroenterology. Klinicheskaya meditsina 2015; 10: 5–13 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Циммерман Я.С. Рак поджелудочной железы: Terra incognita современной гастроэнтерологии. Клиническая медицина 2015; 10: 5–13.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2017. CA Cancer J. Clin. 2017; 67: 7–30.</mixed-citation><mixed-citation xml:lang="ru">Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2020. CA Cancer J. Clin. 2020; 70: 7–30.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><mixed-citation>Hidalgo M., Cascinu S., Kleeff J., Labianca R., Löhr J.M., Neoptolemos J., Real F.X., Van Laethem J.L., Heinemann V. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology 2015; 1: 8–18.</mixed-citation></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Pokataev I. A., Gladkov O. A., Zagaynov V. E., Kudashkin N. E., Lyadov V. K., Patyutko Yu. I., Podluzhnyy D. V., Tryakin A. A., Chernykh M. V. Practical recommendations for drug treatment of pancreatic cancer. Zlokachestvennye opukholi: Prakticheskie rekomendatsii RUSSCO #3s2 2020; 10.27 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Покатаев И. А., Гладков О. А., Загайнов В. Е., Кудашкин Н. Е., Лядов В. К., Патютко Ю. И., Подлужный Д. В., Трякин А. А., Черных М. В. Практические рекомендации по лекарственному лечению рака поджелудочной железы. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2020; 10: 27.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><mixed-citation>Kamisawa T., Wood L.D., Itoi T., Takaori K. Pancreatic cancer. Lancet 2016; 388: 73–85.</mixed-citation></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Hart P.A., Chari S.T. Is Screening for Pancreatic Cancer in High-Risk Individuals One Step Closer or a Fool's Errand? Clin Gastroenterol. Hepatol. 2019; 17: 36–38.</mixed-citation><mixed-citation xml:lang="ru">Hart P.A., Chari S.T. Is Screening for Pancreatic Cancer in High-Risk Individuals One Step Closer or a Fool's Errand? Clin. Gastroenterol. Hepatol. 2019; 17: 36–38.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Patel N., Petrinic T., Silva M., Soonawalla Z., Reddy S., Gordon-Weeks A. The Diagnostic Accuracy of Mutant KRAS Detection from Pancreatic Secretions for the Diagnosis of Pancreatic Cancer: A Meta-Analysis. Cancers (Basel) 2020; 12: 2353.</mixed-citation><mixed-citation xml:lang="ru">Patel N., Petrinic T., Silva M., Soonawalla Z., Reddy S., Gordon-Weeks A. The Diagnostic Accuracy of Mutant KRAS Detection from Pancreatic Secretions for the Diagnosis of Pancreatic Cancer: A Meta-Analysis. Cancers (Basel). 2020; 12: 2353.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Poruk K.E., Gay D.Z., Brown K., Mulvihill J.D., Boucher K.M., Scaife C.L., Firpo M.A., Mulvihill S.J. The clinical utility of CA 19–9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr. Mol. Med. 2013; 13: 340–351.</mixed-citation><mixed-citation xml:lang="ru">Poruk K.E., Gay D.Z., Brown K., Mulvihill J.D., Boucher K.M., Scaife C.L., Firpo M.A., Mulvihill S.J. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr. Mol. Med. 2013; 13: 340–351.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Kim J.E., Lee K.T., Lee J.K., Paik S.W., Rhee J.C., Choi K.W. Clinical usefulness of carbohydrate antigen 19–9 as a screening test for pancreatic cancer in an asymptomatic population. Journal of gastroenterology and hepatology 2004; 2: 182–186.</mixed-citation><mixed-citation xml:lang="ru">Kim J.E., Lee K.T., Lee J.K., Paik S.W., Rhee J.C., Choi K.W. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. Journal of gastroenterology and hepatology 2004; 2: 182–186.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Wu E., Zhou S., Bhat K., Ma Q. CA 19–9 and pancreatic cancer. Clin. Adv. Hematol. Oncol. 2013; 1: 53–55.</mixed-citation><mixed-citation xml:lang="ru">Wu E., Zhou S., Bhat K., Ma Q. CA 19-9 and pancreatic cancer. Clin. Adv. Hematol. Oncol. 2013; 1: 53–55.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><mixed-citation>Swords D.S., Firpo M.A., Scaife C.L., Mulvihill S.J. Biomarkers in pancreatic adenocarcinoma: current perspectives. Onco. Targets Ther. 2016; 9: 7459–7467.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Khan M.A., Zubair H., Srivastava S.K., Singh S., Singh A.P. Insights into the Role of microRNAs in Pancreatic Cancer Pathogenesis: Potential for Diagnosis, Prognosis, and Therapy. Advances in Experimental Medicine and Biology 2015; 889: 71–87.</mixed-citation></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Lee E.J., Gusev Y., Jiang J., Nuovo G.J., Lerner M.R., Frankel W.L., Morgan D.L., Postier R.G., Brackett D.J., Schmittgen T.D. Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer. 2007; 120: 1046–1054.</mixed-citation><mixed-citation xml:lang="ru">Lee E.J., Gusev Y., Jiang J., Nuovo G.J., Lerner M.R., Frankel W.L., Morgan D.L., Postier R.G., Brackett D.J., Schmittgen T.D. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007; 120: 1046–1054.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><mixed-citation>Bloomston M., Frankel W.L., Petrocca F., Volinia S., Alder H., Hagan J.P., Liu C.G., Bhatt D., Taccioli C., Croce C.M. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007; 297: 1901–1908.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Conrad C., Fernández-Del Castillo C. Preoperative evaluation and management of the pancreatic head mass. J. Surg. Oncol. 2013; 1: 23–32.</mixed-citation></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Ashida R., Tanaka S., Yamanaka H., Okagaki S., Nakao K., Fukuda J., Nakao M., Ioka T., Katayama K. The Role of Transabdominal Ultrasound in the Diagnosis of Early Stage Pancreatic Cancer: Review and Single-Center Experience. Diagnostics (Basel). 2018; 1: 2.</mixed-citation><mixed-citation xml:lang="ru">Ashida R., Tanaka S., Yamanaka H., Okagaki S., Nakao K., Fukuda J., Nakao M., Ioka T., Katayama K. The Role of Transabdominal Ultra-sound in the Diagnosis of Early Stage Pancreatic Cancer: Review and Single-Center Experience. Diagnostics (Basel). 2018; 1: 2.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><mixed-citation>Rösch T., Lorenz R., Braig C., Feuerbach S., Siewert J.R., Schusdziarra V., Classen M. Endoscopic ultrasound in pancreatic tumor diagnosis. Gastrointest Endosc. 1991; 3: 347–352.</mixed-citation></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Gonzalo-Marin J., Vila J.J., Perez-Miranda M. Role of endoscopic ultrasound in the diagnosis of pancreatic cancer. World J. Gastrointest Oncol. 2014; 9: 360–368.</mixed-citation><mixed-citation xml:lang="ru">Gonzalo-Marin J., Vila J.J., Perez-Miranda M. Role of endoscopic ultrasound in the diagnosis of pancreatic cancer. World J Gastrointest Oncol. 2014; 9: 360–368.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Maev I.V., Kucheryavyy Yu.A. Diseases of the pancreas. Moscow: GEOTAR-Media 2009 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Маев И. В., Кучерявый Ю. А. Болезни поджелудочной железы. М.: ГЭОТАР-Медиа 2009.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Gangi A.; Malafa M. Klapman J. Endoscopic Ultrasound–Based Pancreatic Cancer Screening of High-Risk Individuals: A Prospective Observational Trial. Pancreas. 2018; 5: 586–591.</mixed-citation><mixed-citation xml:lang="ru">Gangi A., Malafa M., Klapman J. Endoscopic Ultrasound–Based Pancreatic Cancer Screening of High-Risk Individuals: A Prospective Observational Trial. Pancreas. 2018; 5: 586–591.</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><mixed-citation>Gangi S., Fletcher J.G., Nathan M.A., Christensen J.A., Harmsen W.S., Crownhart B.S., Chari S.T. Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. AJR Am. J. Roentgenol. 2004; 4: 897–903.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>US Preventive Services Task Force, Owens D.K., Davidson K.W., Krist A.H., Barry M.J., Cabana M., Caughey A.B., Curry S.J., Doubeni C.A., Epling J.W. Jr, Kubik M., Landefeld C.S., Mangione C.M., Pbert L., Silverstein M., Simon M.A., Tseng C.W., Wong J.B. Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA 2019; 5: 438–444.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Miura S., Takikawa T., Kikuta K., Hamada S., Kume K., Yoshida N., Tanaka Y., Matsumoto R., Ikeda M., Kataoka F., Sasaki A., Hatta W., Inoue J., Masamune A. Focal Parenchymal Atrophy of the Pancreas Is Frequently Observed on Pre-Diagnostic Computed Tomography in Patients with Pancreatic Cancer: A Case-Control Study. Diagnostics (Basel). 2021; 9: 1693.</mixed-citation></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Costache M.I., Costache C.A., Dumitrescu C.I., Tica A.A., Popescu M., Baluta E.A., Anghel A.C., Saftoiu A., Dumitrescu D. Which is the Best Imaging Method in Pancreatic Adenocarcinoma Diagnosis and Staging – CT, MRI or EUS? Curr. Health Sci. J. 2017; 2: 132–136.</mixed-citation><mixed-citation xml:lang="ru">Costache M.I., Costache C.A., Dumitrescu C.I., Tica A.A., Popescu M., Baluta E.A., Anghel A.C., Saftoiu A., Dumitrescu D. Which is the Best Imaging Method in Pancreatic Adenocarcinoma Diagnosis and Staging – CT, MRI or EUS? Curr Health Sci. J. 2017; 2: 132–136.</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><mixed-citation>De Souza A., Irfan K., Masud F., Saif M.W. Diabetes Type 2 and Pancreatic Cancer: A History Unfolding. JOP 2016; 2: 144–148.</mixed-citation></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Li Y., Bian X., Wei S., He M., Yang Y. The relationship between pancreatic cancer and type 2 diabetes: cause and consequence. Cancer. Manag. Res. 2019; 11: 8257–8268.</mixed-citation><mixed-citation xml:lang="ru">Li Y., Bian X., Wei S., He M., Yang Y. The relationship between pancreatic cancer and type 2 diabetes: cause and consequence. Cancer Manag. Res. 2019; 11: 8257–8268.</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><mixed-citation>Li D., Tang H., Hassan M.M., Holly E.A., Bracci P.M., Silverman D.T. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control. 2011; 2: 189–197.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Li D. Diabetes and pancreatic cancer. Mol. Carcinog. 2012; 1: 64–74.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Bergmann U., Funatomi H., Yokoyama M., Beger H.G., Korc M. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res. 1995; 10: 2007–2011.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Suzuki H., Li Y., Dong X., Hassan M.M., Abbruzzese J.L., Li D. Effect of insulin-like growth factor gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2008; 12: 3467–3473.</mixed-citation></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">Andersen D.K., Korc M., Petersen G.M., Eibl G., Li D., Rickels M.R., Chari S.T., Abbruzzese J.L. Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. Diabetes. 2017; 5: 1103–1110.</mixed-citation><mixed-citation xml:lang="ru">Andersen D.K., Korc M., Petersen G.M., Eibl G., Li D, Rickels M.R., Chari S.T., Abbruzzese J.L. Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. Diabetes. 2017; 5: 1103–1110.</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><mixed-citation>Ogihara T., Asano Т., Katagiri H., Sakoda H., Anai M., Shojima N., Ono H., Fujishiro M., Kushiyama A., Fukushima Y., Kikuchi M., Noguchi N., Aburatani H., Gotoh Y., Komuro I., Fujita T. Oxidative stress induces insulin resistance by activating the nuclear factor-? B pathway and disrupting normal subcellular distribution of phosphatidylinositol 3-kinase. Diabetologia 2004; 47: 794–805.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Bastard J.P., Maachi M., Lagathu C., Kim M.J., Caron M., Vidal H., Capeau J., Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 2006; 1: 4–12.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Gopaul N.K., Manraj M.D., Hébé A., Lee Kwai Yan S., Johnston A., Carrier M.J., Anggård E.E. Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. Diabetologia 2001; 6: 706–712.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Ohmura E., Okada M., Onoda N., Kamiya Y., Murakami H., Tsushima T., Shizume K. Insulin-like growth factor I and transforming growth factor alpha as autocrine growth factors in human pancreatic cancer cell growth. Cancer Res. 1990; 50: 103–107.</mixed-citation></ref><ref id="B39"><label>39.</label><citation-alternatives><mixed-citation xml:lang="en">Stoeltzing O., Liu W., Reinmuth N., Fan F., Parikh AA, Bucana C.D., Evans D.B., Semenza G.L., Ellis L.M. Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am. J. Pathol. 2003; 3: 1001–1011.</mixed-citation><mixed-citation xml:lang="ru">Stoeltzing O., Liu W., Reinmuth N., Fan F., Parikh A.A., Bucana C.D., Ev-ans D.B., Semenza G.L., Ellis L.M. Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am. J. Pathol. 2003; 3: 1001–1011.</mixed-citation></citation-alternatives></ref><ref id="B40"><label>40.</label><citation-alternatives><mixed-citation xml:lang="en">Zeng H., Datta K., Neid M., Li J., Parangi S., Mukhopadhyay D. Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. Biochem. Biophys. Res. Commun. 2003; 1: 46–55.</mixed-citation><mixed-citation xml:lang="ru">Zeng H., Datta K., Neid M., Li J., Parangi S., Mukhopadhyay D. Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. Biochem Biophys Res. Commun. 2003; 1: 46–55.</mixed-citation></citation-alternatives></ref><ref id="B41"><label>41.</label><mixed-citation>Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer. 2008; 12: 915–28.</mixed-citation></ref><ref id="B42"><label>42.</label><citation-alternatives><mixed-citation xml:lang="en">Stolzenberg-Solomon R.Z., Limburg P., Pollak M., Taylor PR, Virtamo J., Albanes D. Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. Cancer Epidemiol. Biomarkers Prev. 2004; 3: 438–44.</mixed-citation><mixed-citation xml:lang="ru">Stolzenberg-Solomon R.Z., Limburg P., Pollak M., Taylor P.R., Virtamo J., Albanes D. Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. Cancer Epidemiol Bi-omarkers Prev. 2004; 3: 438–44.</mixed-citation></citation-alternatives></ref><ref id="B43"><label>43.</label><mixed-citation>Wolpin B.M., Michaud D.S., Giovannucci E.L., Schernhammer E.S., Stampfer M.J., Manson J.E., Cochrane B.B., Rohan T.E., Ma J., Pollak M.N., Fuchs C.S. Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts. Br. J. Cancer. 2007; 1: 98–104.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Wolpin B.M., Michaud D.S., Giovannucci E.L., Schernhammer E.S., Stampfer M.J., Manson J.E., Cochrane B.B., Rohan T.E., Ma J., Pollak M.N., Fuchs C.S. Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. Cancer Res. 2007; 16: 7923–7928.</mixed-citation></ref><ref id="B45"><label>45.</label><citation-alternatives><mixed-citation xml:lang="en">Pfeffer F., Koczan D., Adam U., Benz S., von Dobschuetz E., Prall F., Nizze H., Thiesen H.J., Hopt U.T., Löbler M. Expression of connexin26 in islets of Langerhans is associated with impaired glucose tolerance in patients with pancreatic adenocarcinoma. Pancreas. 2004; 29: 284–290.</mixed-citation><mixed-citation xml:lang="ru">Pfeffer F., Koczan D., Adam U., Benz S., von Dobschuetz E., Prall F., Nizze H., Thiesen H.J., Hopt U.T., Löbler M. Expression of connexin 26 in islets of Langerhans is associated with impaired glucose tolerance in patients with pancreatic adenocarcinoma. Pancreas. 2004; 29: 284–290.</mixed-citation></citation-alternatives></ref><ref id="B46"><label>46.</label><mixed-citation>Permert J., Larsson J., Fruin A.B., Tatemoto K., Herrington M.K, von Schenck H., Adrian T.E. Islet hormone secretion in pancreatic cancer patients with diabetes. Pancreas. 1997; 15: 60–68.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Permert J., Larsson J., Westermark G.T., Herrington M.K., Christmanson L., Pour P.M., Westermark P., Adrian T.E. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N. Engl. J. Med. 1994; 330: 313–318.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Chari S.T., Klee G.G., Miller L.J., Raimondo M., DiMagno E.P. Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. Gastroenterology 2001; 121: 640–645.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Aggarwal G., Rabe K.G., Petersen G.M., Chari S.T. New-onset diabetes in pancreatic cancer: a study in the primary care setting. Pancreatology 2012; 12: 156–161.</mixed-citation></ref><ref id="B50"><label>50.</label><citation-alternatives><mixed-citation xml:lang="en">American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes care. 2020; 43: 14–31.</mixed-citation><mixed-citation xml:lang="ru">American Diabetes Association 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes care 2020; 43: 14–31.</mixed-citation></citation-alternatives></ref><ref id="B51"><label>51.</label><mixed-citation>Samuels T.A., Cohen D., Brancati F.L., Coresh J., Kao W.H. Delayed diagnosis of incident type 2 diabetes mellitus in the ARIC study. Am. J. Manag. Care. 2006; 12: 717–724.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Everhart J., Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995; 273: 1605–1609.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Huxley R., Ansary-Moghaddam A., Berrington de González A., Barzi F., Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br. J. Cancer. 2005; 92: 2076–2083.</mixed-citation></ref><ref id="B54"><label>54.</label><citation-alternatives><mixed-citation xml:lang="en">Gupta S., Vittinghoff E., Bertenthal D., Corley D., Shen H., Walter L.C., McQuaid K. New-onset diabetes and pancreatic cancer. Clin. Gastroenterol. Hepatol. 2006; 4: 1366–1372.</mixed-citation><mixed-citation xml:lang="ru">Gupta S., Vittinghoff E., Bertenthal D., Corley D., Shen H., Walter L.C., McQuaid K. New-onset diabetes and pancreatic cancer. Clin. Gastroen-terol Hepatol. 2006; 4: 1366–1372.</mixed-citation></citation-alternatives></ref><ref id="B55"><label>55.</label><mixed-citation>Chari S.T., Leibson C.L., Rabe K.G., Timmons L.J., Ransom J., de Andrade M., Petersen G.M. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008; 134: 95–101.</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Pannala R., Leirness J.B., Bamlet W.R., Basu A., Petersen G.M., Chari S.T. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008; 134: 981–987.</mixed-citation></ref><ref id="B57"><label>57.</label><citation-alternatives><mixed-citation xml:lang="en">Kashintsev A.A., Kokhanenko N.Yu. Relationship between diabetes mellitus and pancreatic cancer. Sibirskiy onkologicheskiy zhurnal 2013; 4: 36–39 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Кашинцев А.А., Коханенко Н.Ю. Взаимосвязь между сахарным диабетом и раком поджелудочной железы. Сибирский онкологический журнал 2013; 4: 36–39.</mixed-citation></citation-alternatives></ref><ref id="B58"><label>58.</label><citation-alternatives><mixed-citation xml:lang="en">Pelaez-Luna M., Takahashi N., Fletcher J.G., Chari S.T. Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am. J. Gastroenterol 2007; 102: 2157–2163.</mixed-citation><mixed-citation xml:lang="ru">Pelaez-Luna M., Takahashi N., Fletcher J.G., Chari S.T. Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am. J. Gastroenterol. 2007; 102: 2157–2163.</mixed-citation></citation-alternatives></ref><ref id="B59"><label>59.</label><mixed-citation>Sharma A., Kandlakunta H., Nagpal S.J.S., Feng Z., Hoos W., Petersen G.M., Chari S.T. Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. Gastroenterology 2018; 155: 730–739.</mixed-citation></ref></ref-list></back></article>
